Moderna, Inc. (MRNA) Stock Score, Valuation & Financial Research
Moderna, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 20/100.
Quick answer for MRNA
Moderna, Inc. currently has a Wall Street Score of 20/100. The stored market price is $146.69. Its financial score is 20/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Moderna, Inc. does
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic
MRNA financial snapshot
- Wall Street Score:
- 20/100
- Current price:
- $146.69
- Market capitalization:
- $58.20B
- Revenue:
- $2.23B
- Net income:
- $-3.19B
- Free cash flow:
- $-2.06B
- Cash:
- $1.91B
- Total debt:
- $1.30B
- EPS:
- -7.26
- Financial score:
- 20/100
- Valuation score:
- 0/100
- Revenue score:
- 15/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-2.06B, showing cash burn in the current stored period.
- The balance sheet shows $1.91B of cash versus $1.30B of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 20/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research MRNA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.